User menu

Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression

Bibliographic reference Vardeny, O. ; Pouleur, Anne-Catherine ; Takeuchi, M. ; Appelbaum, E. ; Verma, A. ; et. al. Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression. In: Journal of the Renin-Angiotensin-Aldosterone System, Vol. 13, no. 2, p. 265-272 (2012)
Permanent URL http://hdl.handle.net/2078.1/122432
  1. D'Agostino Ralph B, Russell Mason W, Huse Daniel M, Ellison R.Curtis, Silbershatz Halit, Wilson Peter W.F, Hartz Stuart C, Primary and subsequent coronary risk appraisal: New results from the Framingham study, 10.1016/s0002-8703(00)90236-9
  2. Jacoby Richard M., Nesto Richard W., Acute myocardial infarction in the diabetic patient: Pathophysiology, clinical course and prognosis, 10.1016/0735-1097(92)90033-j
  3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), 10.1016/s0140-6736(98)07019-6
  4. Alderman M. H., Cohen H., Madhavan S., Diabetes and Cardiovascular Events in Hypertensive Patients, 10.1161/01.hyp.33.5.1130
  5. Epstein M., Sowers J. R., Diabetes mellitus and hypertension, 10.1161/01.hyp.19.5.403
  6. Destefano Frank, Ford Earl S., Newman Jeffrey, Stevenson John M., Wetterhall Scott F., Anda Robert F., Vinicor Frank, Risk factors for coronary heart disease mortality among persons with diabetes, 10.1016/1047-2797(93)90006-p
  7. Levy Daniel, Garrison Robert J., Savage Daniel D., Kannel William B., Castelli William P., Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart Study, 10.1056/nejm199005313222203
  8. Vakili Babak A., Okin Peter M., Devereux Richard B., Prognostic implications of left ventricular hypertrophy, 10.1067/mhj.2001.113218
  9. Korner Paul I., Jennings Garry L., Assessment of prevalence of left ventricular hypertrophy in hypertension : , 10.1097/00004872-199816060-00001
  10. Devereux Richard B., Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension, 10.1001/jama.292.19.2350
  11. Chobanian Aram V., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 Report, 10.1001/jama.289.19.2560
  12. Luetscher John A., Kraemer Fredric B., Wilson Darrell M., Schwartz Herbert C., Bryer-Ash Michael, Increased Plasma Inactive Renin in Diabetes Mellitus : A Marker of Microvascular Complications, 10.1056/nejm198505303122202
  13. Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients, 10.1056/nejm200001203420301
  14. Parving Hans-Henrik, Lehnert Hendrik, Bröchner-Mortensen Jens, Gomis Ramon, Andersen Steen, Arner Peter, The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes, 10.1056/nejmoa011489
  15. Lewis Edmund J., Hunsicker Lawrence G., Bain Raymond P., Rohde Richard D, The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy, 10.1056/nejm199311113292004
  16. Hollenberg Norman K., Price Deborah A., Fisher Naomi D.L., Lansang M. Cecilia, Perkins Bruce, Gordon Michael S., Williams Gordon H., Laffel Lori M.B., Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus, 10.1046/j.1523-1755.2003.00701.x
  17. Stevanovic Radomir D, Price Deborah A, Lansang M Cecilia, Fisher Naomi DL, Laffel Lori MB, Hollenberg Norman K, Renin Release in Response to Renin System Blockade: Activation of the Renin System in Type 1 Diabetes Mellitus, 10.3317/jraas.2005.013
  18. Alderman M, Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients, 10.1016/j.amjhyper.2003.08.015
  19. Singh A. B., Sugimoto K., Dhawan P., Harris R. C., Juxtacrine activation of EGFR regulates claudin expression and increases transepithelial resistance, 10.1152/ajpcell.00274.2007
  20. Siragy Helmy M., Huang Jiqian, Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1receptor and NADPH oxidase activity : Renal (pro)renin receptors in diabetes, 10.1113/expphysiol.2007.040550
  21. Burckle C. A., Jan Danser A.H., Muller D. N., Garrelds I. M., Gasc J.-M., Popova E., Plehm R., Peters J., Bader M., Nguyen G., Elevated Blood Pressure and Heart Rate in Human Renin Receptor Transgenic Rats, 10.1161/01.hyp.0000199912.47657.04
  22. Solomon S. D., Appelbaum E., Manning W. J., Verma A., Berglund T., Lukashevich V., Cherif Papst C., Smith B. A., Dahlof B., , Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy, 10.1161/circulationaha.108.826214
  23. Alfakih Khaled, Plein Sven, Thiele Holger, Jones Tim, Ridgway John P., Sivananthan Mohan U., Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences, 10.1002/jmri.10262
  24. Grossman Ehud, Left Ventricular Mass in Diabetes-Hypertension, 10.1001/archinte.1992.00400170085016
  25. Okin Peter M., Wachtell Kristian, Devereux Richard B., Harris Katherine E., Jern Sverker, Kjeldsen Sverre E., Julius Stevo, Lindholm Lars H., Nieminen Markku S., Edelman Jonathan M., Hille Darcy A., Dahlöf Björn, Regression of Electrocardiographic Left Ventricular Hypertrophy and Decreased Incidence of New-Onset Atrial Fibrillation in Patients With Hypertension, 10.1001/jama.296.10.1242
  26. Parving Hans-Henrik, Persson Frederik, Lewis Julia B., Lewis Edmund J., Hollenberg Norman K., Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy, 10.1056/nejmoa0708379
  27. Persson F., Rossing P., Reinhard H., Juhl T., Stehouwer C. D.A., Schalkwijk C., Danser A.H. J., Boomsma F., Frandsen E., Parving H.-H., Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria, 10.2337/dc09-0168
  28. Solomon Scott D., Hee Shin Sung, Shah Amil, Skali Hicham, Desai Akshay, Kober Lars, Maggioni Aldo P., Rouleau Jean L., Kelly Roxzana Y., Hester Allen, McMurray John J.V., Pfeffer Marc A., Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction, 10.1093/eurheartj/ehq522
  29. Parving H.-H., Brenner B. M., McMurray John. J. V., de Zeeuw D., Haffner S. M., Solomon S. D., Chaturvedi N., Ghadanfar M., Weissbach N., Xiang Z., Armbrecht J., Pfeffer M. A., Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design, 10.1093/ndt/gfn721
  30. Krum H, Eur J Heart Fail, 13, 107 (2011)
  31. Okin P. M., Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study, 10.1161/circulationaha.105.574822
  32. Devereux R. B., Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial, 10.1161/01.cir.0000141573.44737.5a
  33. Gordon Michael S, Price Deborah A, Hollenberg Norman K, Blunted suppression of plasma renin activity in diabetes, 10.3317/jraas.2000.038
  34. Price DA, J Am Soc Nephrol, 10, 2382 (1999)
  35. Feldman D. L., Jin L., Xuan H., Contrepas A., Zhou Y., Webb R. L., Mueller D. N., Feldt S., Cumin F., Maniara W., Persohn E., Schuetz H., Jan Danser A.H., Nguyen G., Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats, 10.1161/hypertensionaha.107.108845
  36. Kelly D. J., Zhang Y., Moe G., Naik G., Gilbert R. E., Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats, 10.1007/s00125-007-0795-9
  37. Dong Y. F., Liu L., Kataoka K., Nakamura T., Fukuda M., Tokutomi Y., Nako H., Ogawa H., Kim-Mitsuyama S., Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes, 10.1007/s00125-009-1575-5
  38. Weber K. T., Brilla C. G., Pathological hypertrophy and cardiac interstitium. Fibrosis and renin- angiotensin-aldosterone system, 10.1161/01.cir.83.6.1849
  39. Brilla C. G., Pick R., Tan L. B., Janicki J. S., Weber K. T., Remodeling of the rat right and left ventricles in experimental hypertension, 10.1161/01.res.67.6.1355
  40. Brilla CG, J Lab Clin Med, 120, 893 (1992)
  41. Pouleur Anne-Catherine, Uno Hajime, Prescott Margaret F, Desai Akshay, Appelbaum Evan, Lukashevich Valentina, Smith Beverly A, Dahlöf Björn, Solomon Scott D, , Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension, 10.1177/1470320311414453
  42. Krum Henry, Massie Barry, Abraham William T., Dickstein Kenneth, Kober Lars, McMurray John J.V., Desai Ashkay, Gimpelewicz Claudio, Kandra Albert, Reimund Bernard, Rattunde Henning, Armbrecht Juergen, , Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOS, 10.1093/eurjhf/hfq212